Ankit Tripathi
@huji.ac.il
Post-Doctoral Research Fellow (PDRF)
Hebrew University, Jerusalem
Ankit Tripathi has a background in Mammalian physiology, focusing on redox biology & inflammation-mediated pulmonary morbidities and their therapeutic interventions by assessing specific biomarkers using biochemistry and molecular biology modalities.
He completed his PhD in Life Sciences with the special emphasis on mammalian lung physiology under low pO2 milieu in 2021 and subsequent postdoctoral trainings from Sir Ganga Ram Hospital New Delhi, University of Delhi North Campus, and Indian Institute of Technology Kanpur (IITK) India before moving to the Faculty of Medicine, Jerusalem at Hebrew University in April 2023.
During this period he published several high impact, peer reviewed articles, and trained more than a dozen of UG/PG/PhD students from life sciences cohort. Additionally he has been felicitated with various awards in distinct national and international conferences from 2014-2023 along with an eminent membership at International Spanish Society for Thrombosis and Homeostas
EDUCATION
(A). July 2015- July 2020: Ph.D. (Life Sciences), Hematology Division, Defence Institute of Physiology & Allied Sciences (DIPAS), Defence Research & Development Organization (DRDO), Delhi, Ministry of Defence, India.
(B). October, 2020- July, 2021: Senior Research Fellow, Department of Research, Sir Ganga Ram Hospital (SGRH), New Delhi, India.
(C). (C). August, 2021- June, 2022: Postdoctoral Research Fellow (PDRF), Department of Molecular Aging of Genetics, Dr. B.R. Ambedkar Center for Biomedical Research (ACBR),University of Delhi, North Campus, Delhi, India.
(D). June 2022- April 2023: Postdoctoral Research Fellow (PDRF), Biological Sciences and Bioengineering Department, Indian Institute of Technology Kanpur (IITK), India.
(E). April 2023- till date: Postdoctoral Research Fellow (PDRF), Faculty of Medicine, Department of Biochemistry & Molecular Biology, Hebrew University of Jerusalem, Jerusalem, Israel.
RESEARCH INTERESTS
1. Respiratory Biology
2. Biochemistry and Molecular Biology
3. Mammalian physiology
Scopus Publications
Scopus Publications
Rashmi Rana, Ankit Tripathi, Naveen Kumar, and Nirmal Kumar Ganguly
Frontiers Media SA
The outbreak of COVID-19 has proven to be an unprecedented disaster for the whole world. The virus has inflicted billion of lives across the globe in all aspects—physically, psychologically, as well as socially. Compared to the previous strains of β-CoV genera- MERS and SARS, SARS-CoV-2 has significantly higher transmissibility and worst post-recovery implications. A frequent mutation in the initial SARS-CoV-2 strain has been a major cause of mortalities (approx. 3 million deaths) and uncontrolled virulence (approx. 1 billion positive cases). As far as clinical manifestations are concerned, this particular virus has exhibited deleterious impacts on systems other than the respiratory system (primary target organ), such as the brain, hematological system, liver, kidneys, endocrine system, etc. with no promising curatives to date. Lack of emergency treatments and shortage of life-saving drugs has promoted the repurposing of existing therapeutics along with the emergence of vaccines with the combined efforts of scientists and industrial experts in this short span. This review summarizes every detail on COVID-19 and emphasizes undermining the future approaches to minimize its prevalence to the remaining lives.
Ankit Tripathi, Bhuvnesh Kumar, and Sarada S.K. Sagi
Elsevier BV
Ankit Tripathi, Puja P. Hazari, Anil K. Mishra, Bhuvnesh Kumar, and Sarada S.K. Sagi
Informa UK Limited
ABSTRACT High altitude pulmonary edema (HAPE) is generally characterized by the loss of alveolar epithelial barrier integrity. The current study was undertaken to assess the noninvasive approaches of HAPE diagnosis and to evaluate the prophylactic potential of quercetin in preventing alveolar junction impairments. Male SD rats fed with quercetin 1 h prior to hypoxia (7,620 m, for 6 h) were selected. PET/CT imaging was performed to visualize the lung uptake of 18F-FDG in animals under hypoxia. Further, oxidant status, catalase activity, hematological & blood gas parameters were evaluated. Moreover, tight junction (TJ) proteins (ZO-1, JAM-C, Claudin-4, and occludin) expression analysis was accomplished using immune-blotting. The structural differences in lung epithelia were noted by TEM imaging. Quercetin prophylaxis has significantly reduced the FDG uptake in rat lungs under hypoxia. It has also dramatically alleviated the protein oxidation followed by an elevation in catalase activity in the lungs under hypoxia. The TJ protein expression in the lungs has also been restored to normal upon quercetin pre-treatment. Concomitantly, the quercetin preconditioning has elicited the stable blood gas and hematological parameters under hypoxia. The observations from TEM imaging have also implicated the normal lung epithelial structures in the quercetin pretreated animals under hypoxia. Quercetin prophylaxis has significantly restored alveolar epithelium integrity by abating oxidative stress in the lungs under hypoxia. Abbreviations: CT- Computed Tomography 18F-FDG- Fluorodeoxyglucose (18FHAPE- High Altitude Pulmonary EdemaHb- HemoglobinHCT- HematocritHCO3 – BicarbonateJAM- Junctional Adhesion MoleculeKBq- Killo BecquerelPaO2 - Partial pressure of arterial oxygenPaCO2 - Partial pressure of arterial carbon di-oxidePET- Positron Emission TomographyRBC- Red Blood CorpusclesSD- Sprague DawleyTJ- Tight JunctionsTEM- Transmission Electron MicroscopyWBC- White Blood CorpusclesZO- Zona Occludin.
Ankit Tripathi, Manoj Kumar, Punit Kaur, Bhuvnesh Kumar, and Sarada S.K. Sagi
Elsevier BV
Ankit Tripathi, Bhuvnesh Kumar, and Sarada S. K. Sagi
Public Library of Science (PLoS)
The objective of the study was to find out the prophylactic efficacy of Quercetin in ameliorating the hypoxia induced vascular leakage in lungs of rats. Male SD rats received different doses of quercetin @ 25mg, 50mg, 100mg and 200mg/Kg BW, 1h prior to hypobaric hypoxia exposure (7,620m, for 6h). Quercetin 50 mg/kg BW supplemented orally 1h prior to hypoxia exposure was considered to be the optimum dose, due to significant reduction (p<0.001) in lung water content and lung transvascular leakage compared to control (hypoxia, 6h). Further, biochemical analysis (ROS, MDA, GSH, GPx, LDH, and albumin) and differential expressions of proteins (IKK-α/β, NFĸB, Nrf-2,TNF-α, ICAM-1, VCAM, P-selectin, Hif-1α, VEGF, TNF-α, TGF-β, INF-γ and IL-4) were determined by western blotting and ELISA. Changes in lung parenchyma were assessed by histopathology. Quercetin (50 mg/kg BW) prophylaxis under hypoxia showed significant reduction in oxidative stress (ROS and MDA), concomitant increase in antioxidants (GSH, GPx and SOD) followed by decreased LDH and albumin extravasation in BAL fluid over hypoxia. Quercetin prophylaxis significantly down regulated hypoxia induced increase in IKKα/β and NFĸB expressions leading to reduction in the levels of pro-inflammatory cytokines (TNF-α and INF-γ) followed by up regulation of anti-inflammatory cytokines (IL-4 and INF-γ) in lungs. Further, hypoxia mediated increase in HIF-1α was stabilized and VEGF levels in lungs were significantly down regulated by quercetin supplementation, leading to reduction in vascular leakage in lungs of rats under hypoxia. However, Quercetin has also enacted as Nrf-2 activator which significantly boosted up the synthesis of GSH under hypoxic condition compared to hypoxia. Histopathological observations further confirmed that quercetin preconditioning has an inhibitory effect on progression of oxidative stress and inflammation via attenuation of NFκB and stabilization HIF-1α in lungs of rats under hypoxia.These studies indicated that quercetin prophylaxis abrogates the possibility of hypobaric hypoxia induced pulmonary edema in rats.
Ankit Tripathi, Renu Sharma, Noopur Kejriwal, Rashmi K. Ambasta, and Pravir Kumar
Springer International Publishing
RECENT SCHOLAR PUBLICATIONS
RESEARCH OUTPUTS (PATENTS, SOFTWARE, PUBLICATIONS, PRODUCTS)
Developed Quercetin Bar (Q-DIP) nutraceutical against High Altitude Pulmonary Edema (HAPE) and other associated respiratory distresses in the host laboratory- DIPAS-DRDO, Delhi India, after its successful pre-clinical, toxicological, and clinical trials. On Oct 5, 2020, the license for agreement transfer of technology (LAToT) has been signed between DIPAS- DRDO and M/s-Sarvotham Care Ltd. Secundrabad, India; Tripathi A,
S. Somnath, Sarada S.K.S, Varshney R. from DIPAS-DRDO performed pre-clinical studies (invitro and invivo), Pharmacology Department from IISER Mohali conducted toxicology, and Department of Research from Sir Ganga Ram Hospital, New Delhi conducted clinical trials.